N30 Pharmaceuticals - Product Pipeline Review - 2013


Naperville, IL -- (SBWIRE) -- 10/08/2013 -- Reportstack, provider of premium market research reports announces the addition of N30 Pharmaceuticals - Product Pipeline Review - 2013 market report to its offering
N30 Pharmaceuticals - Product Pipeline Review - 2013


Global Market Directs pharmaceuticals report, N30 Pharmaceuticals - Product Pipeline Review - 2013 provides data on the N30 Pharmaceuticalss research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, N30 Pharmaceuticalss corporate website, SEC filings, investor presentations and featured press releases, both from N30 Pharmaceuticals and industry-specific third party sources, put together by team.


- N30 Pharmaceuticals - Brief N30 Pharmaceuticals overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of N30 Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of N30 Pharmaceuticals with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the N30 Pharmaceuticalss pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate N30 Pharmaceuticalss strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of N30 Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the N30 Pharmaceuticalss R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with N30 Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of N30 Pharmaceuticals and identify potential opportunities in those areas.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604